3α,21-Dihydroxy-5α-pregnane-11,20-dione
CAS: 14107-37-0
Rif. 3D-FD17323
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione |
Informazioni sul prodotto
- (3α,5α)-3,21-Dihydroxypregnane-11,20-dioneAlphadolone
- (3Α,5Α)-3,21-Dihydroxypregnane-11,20-Dione
- 3-alpha,21-Dihydroxy-5-alpha-pregnane-11,20-dione
- 3alpha,21-Dihydroxy-5alpha-pregnane-11,20-dione
- 5-alpha-Pregnane-11,20-dione, 3-alpha,21-dihydroxy-
- 5α-Pregnane-11,20-dione, 3α,21-dihydroxy-
- 5α-Pregnane-3α,21-diol-11,20-dione
- Alfadolona
- Alfadolona [INN-Spanish]
- Alfadolone [INN:DCF]
- Vedi altri sinonimi
- Alfadolonum
- Alfadolonum [INN-Latin]
- Alphadolone
- Gr 2/1574
- Pregnane-11,20-dione, 3,21-dihydroxy-, (3α,5α)-
- Unii-Oe1C96974E
- Alfadolone
3a,21-Dihydroxy-5a-pregnane-11,20-dione (3A,21P) is a nitrous oxide metabolite produced by the enzyme cytochrome P450. It has been shown to have low potency as an anaesthetic and to have a clinical relevance in the treatment of postoperative pain. 3A,21P has been found to be antinociceptive in animal models and may act through the gamma-aminobutyric acid system. It is also involved in neuronal function and polymorphonuclear leucocytes. 3A,21P is not currently used clinically for any indication. The mechanism of action for this molecule is not known with certainty but it may inhibit the formation of prostaglandins or increase sensitivity to GABA receptors.